德乌克拉维西提尼的有效性和安全性,选择性,全性TYK2抑制剂,根据基线DMARD在第2期牛皮关节炎研究中的使用:后期分析
Atul Deodhar1, Miroslawa Nowak2, June Y Ye3
1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA. deodhara@ohsu.edu.
Rheumatology and therapy
|July 5, 2025
概括
背景 传统的合成修饰疾病的抗风湿药物使用没有影响deucravacitinib在牛皮关节炎患者的疗效或安全性. 这一发现支持deucravacitinib作为PsA的可行的治疗选择,无论之前的csDMARD治疗如何.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮关节炎 (PsA) 是一种慢性炎症状况.
- 传统的合成疾病修饰性抗风湿药物 (csDMARDs) 通常用于PSA管理.
- 背景使用csDMARD对新疗法 (如deucravacitinib) 的影响需要评估.
研究的目的:
- 评估背景csDMARD使用对PsA患者deucravacitinib疗效和安全性的影响.
- 为了确定之前的csDMARD治疗是否会影响deucravacitinib在治疗牛皮关节炎中的性能.
主要方法:
- 一个2期,双盲,随机试验的后期分析,涉及203名PsA患者.
- 患者接受了安慰剂,deucravacitinib 6毫克或deucravacitinib 12毫克每天16周.
- 根据背景使用csDMARD,评估了有效性结果 (ACR 20,PASI,PASDAS) 和安全性.
主要成果:
- 在有或没有背景使用csDMARD的患者之间,基线特征相似.
- 德乌克拉维西替尼 (deucravacitinib) 显示出类似的疗效 (ACR 20,PASI,PASDAS),无论其背景使用了csDMARD.
- 在使用或不使用csDMARD的各个子组中,deucravacitinib的安全性概况保持一致.
结论:
- 背景使用csDMARD不会改变德乌克拉维西提尼布在牛皮性关节炎的疗效.
- 德乌克拉维西提尼的安全性概况不受同时或之前的csDMARD治疗的影响.
- 德乌克拉维西丁尼 (deucravacitinib) 是一种有前途的PsA治疗方法,独立于csDMARD状态.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
238
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
238
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
275
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
01:26Drug Administration and Therapy Phases: Overview
766
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
766
01:24Phase II Reactions: Glucuronidation
813
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
813
01:30Inflammatory Bowel Disease II: Crohn's Disease
395
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
395